Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth CorpfiledCriticalWyeth Corp
Publication of CR9552ApublicationCriticalpatent/CR9552A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
La presente invencion proporciona anticuerpos monoclonales para el TrkB humano. En algunas modalidades los anticuerpos de la invencion unen y activan el TrkB humano. En algunas modalidades de la invencion los anticuerpos son selectivos para el TrkB humano en que no unen ( o activan) el TrkA humano o el TrkC humano. En algunas modalidades los anticuerpos monoclonales presentan reactividad cruzada TrkB murina Versiones humanizadas o figuradas de los anticuerpos tambien son consideradas.The present invention provides monoclonal antibodies to human TrkB. In some embodiments the antibodies of the invention bind and activate human TrkB. In some embodiments of the invention the antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments, monoclonal antibodies have cross-reactivity murine TrkB Humanized or figurative versions of the antibodies are also considered.
CR9552A2006-06-062007-11-29
ANTI-TRKB MONOCLONAL ANTIBODIES AND USES OF THE SAME
CR9552A
(en)
Vaccine kit comprising at least nine conjugates of saccharides of hb or hib antigens, where at least 2-7 are with the crm transporter protein, said kit being suitable for use in their primary immunization schedule; combination vaccine suitable for primary immunization.